Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Comparative Studies Will Be Funded By Neurontin Settlement

Executive Summary

The Pfizer Neurontin off-label promotion settlement will fund $28 mil. in comparative efficacy studies for prescription drug products
Advertisement

Related Content

Academic Archive of Pharma Marketing Data On Hold Without Funding
Neurontin Off-Label Suit: Plaintiffs’ Experts Claim Pfizer Slanted Studies
Pharmacia Is First Manufacturer Busted For Receiving Kickbacks From A PBM
Off-Label Use Study Prompts Disagreement On Both Problem And Solution
Neurontin Settlement Money Funding Research On Impact Of Drug Marketing
Serostim $704 Mil. Settlement Is Largest For Off-Label Marketing Case
State AGs To Discuss Drug Pricing, Marketing At January Summit
Warner-Lambert GMP Conviction Plays Role In Neurontin Case
Warner-Lambert GMP Conviction Plays Role In Neurontin Case
Pfizer Ready To Settle Neurontin Promotion Case; Reserves $427 Mil.
Advertisement
UsernamePublicRestriction

Register

PS043994

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel